Clinical observation and comparison of intravenous and oral azithromycin treatment of pediatric community-acquired pneumonia

Observation and comparison of adverse reactions and efficacy of intravenous and oral azithromycin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004769

Enrollment

Unknown

Registered

2014-06-05

Start date

2014-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric community-acquired pneumonia

Interventions

experimental group(intravenous azithromycin group):Give patients a daily injection of azithromycin 8 ~ 12mg / kg

control group(oral azithromycin group):Give patients oral azithromycin 5 ~ 10mg / kg per day

Eligibility

Sex/Gender

All

Age

No minimum to 10 Years

Inclusion criteria

Inclusion criteria: The emergency patients, out-patients and in-patients aged 0-10,of which the clinical diagnosis are community-acquired pneumonia.

Exclusion criteria

Exclusion criteria: Serious liver and kidney dysfunction, other causes of lung disease.

Design outcomes

Primary

Measure	Time frame
adverse reactions;efficacy;	—

Countries

China

Contacts

Public ContactLi Zhiping

Children's Hospital of Fudan University

zhipinglifudan@yeah.net+86 021 64932030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026